AIDS clinical trials group 5197: A placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein

Robert T. Schooley, John Spritzler, Hongying Wang, Michael M. Lederman, Diane Havlir, Daniel R. Kuritzkes, Richard B Pollard, Cathy Battaglia, Michael Robertson, Devan Mehrotra, Danilo Casimiro, Kara Cox, Barbara Schock

Research output: Contribution to journalArticle

61 Citations (Scopus)

Abstract

Background. Human immunodeficiency virus type 1 (HIV-1)-specific cellular immunity contributes to the control of HIV-1 replication. HIV-1-infected volunteers who were receiving antiretroviral therapy were given a replication-defective adenovirus type 5 HIV-1 gag vaccine in a randomized, blinded therapeutic vaccination study. Methods. HIV-1-infected vaccine or placebo recipients underwent analytical treatment interruption (ATI) for 16 weeks. The log10 HIV-1 RNA load at the ATI set point and the time-averaged area under the curve served as coprimary end points. Immune responses were measured by intracellular cytokine staining and carboxyfluorescein succinimidyl ester dye dilution. Results. Vaccine benefit trends were seen for both primary end points, but they did not reach a prespecified significance level of . The estimated P ≤.025 shifts in the time-averaged area under the curve and the ATI set point were 0.24 (P=.04 , unadjusted) and 0.26 ( P=.07, unadjusted) log10 Pp.04 Pp.07 copies lower, respectively, in the vaccine arm than in the placebo arm. HIV-1 gag-specific CD4+ cells producing interferon-γ were an immunologic correlate of viral control. Conclusion. The vaccine was generally safe and well tolerated. Despite a trend favoring viral suppression among vaccine recipients, differences in HIV-1 RNA levels did not meet the prespecified level of significance. Induction of HIV-1 gag-specific CD4 cells correlated with control of viral replication in vivo. Future immunogenicity studies should require a substantially higher immunogenicity threshold before an ATI is contemplated.

Original languageEnglish (US)
Pages (from-to)705-716
Number of pages12
JournalJournal of Infectious Diseases
Volume202
Issue number5
DOIs
StatePublished - Sep 1 2010

Fingerprint

Adenovirus Vaccines
Viral Core Proteins
HIV-1
Immunization
Acquired Immunodeficiency Syndrome
Placebos
Clinical Trials
Vaccines
Area Under Curve
Therapeutics
RNA
Virus Replication
Adenoviridae
Cellular Immunity
Interferons
Volunteers
Esters
Vaccination
Coloring Agents

ASJC Scopus subject areas

  • Infectious Diseases
  • Immunology and Allergy

Cite this

AIDS clinical trials group 5197 : A placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. / Schooley, Robert T.; Spritzler, John; Wang, Hongying; Lederman, Michael M.; Havlir, Diane; Kuritzkes, Daniel R.; Pollard, Richard B; Battaglia, Cathy; Robertson, Michael; Mehrotra, Devan; Casimiro, Danilo; Cox, Kara; Schock, Barbara.

In: Journal of Infectious Diseases, Vol. 202, No. 5, 01.09.2010, p. 705-716.

Research output: Contribution to journalArticle

Schooley, RT, Spritzler, J, Wang, H, Lederman, MM, Havlir, D, Kuritzkes, DR, Pollard, RB, Battaglia, C, Robertson, M, Mehrotra, D, Casimiro, D, Cox, K & Schock, B 2010, 'AIDS clinical trials group 5197: A placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein', Journal of Infectious Diseases, vol. 202, no. 5, pp. 705-716. https://doi.org/10.1086/655468
Schooley, Robert T. ; Spritzler, John ; Wang, Hongying ; Lederman, Michael M. ; Havlir, Diane ; Kuritzkes, Daniel R. ; Pollard, Richard B ; Battaglia, Cathy ; Robertson, Michael ; Mehrotra, Devan ; Casimiro, Danilo ; Cox, Kara ; Schock, Barbara. / AIDS clinical trials group 5197 : A placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein. In: Journal of Infectious Diseases. 2010 ; Vol. 202, No. 5. pp. 705-716.
@article{c4a801d6ef26405fbf5e9afc7d06722a,
title = "AIDS clinical trials group 5197: A placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein",
abstract = "Background. Human immunodeficiency virus type 1 (HIV-1)-specific cellular immunity contributes to the control of HIV-1 replication. HIV-1-infected volunteers who were receiving antiretroviral therapy were given a replication-defective adenovirus type 5 HIV-1 gag vaccine in a randomized, blinded therapeutic vaccination study. Methods. HIV-1-infected vaccine or placebo recipients underwent analytical treatment interruption (ATI) for 16 weeks. The log10 HIV-1 RNA load at the ATI set point and the time-averaged area under the curve served as coprimary end points. Immune responses were measured by intracellular cytokine staining and carboxyfluorescein succinimidyl ester dye dilution. Results. Vaccine benefit trends were seen for both primary end points, but they did not reach a prespecified significance level of . The estimated P ≤.025 shifts in the time-averaged area under the curve and the ATI set point were 0.24 (P=.04 , unadjusted) and 0.26 ( P=.07, unadjusted) log10 Pp.04 Pp.07 copies lower, respectively, in the vaccine arm than in the placebo arm. HIV-1 gag-specific CD4+ cells producing interferon-γ were an immunologic correlate of viral control. Conclusion. The vaccine was generally safe and well tolerated. Despite a trend favoring viral suppression among vaccine recipients, differences in HIV-1 RNA levels did not meet the prespecified level of significance. Induction of HIV-1 gag-specific CD4 cells correlated with control of viral replication in vivo. Future immunogenicity studies should require a substantially higher immunogenicity threshold before an ATI is contemplated.",
author = "Schooley, {Robert T.} and John Spritzler and Hongying Wang and Lederman, {Michael M.} and Diane Havlir and Kuritzkes, {Daniel R.} and Pollard, {Richard B} and Cathy Battaglia and Michael Robertson and Devan Mehrotra and Danilo Casimiro and Kara Cox and Barbara Schock",
year = "2010",
month = "9",
day = "1",
doi = "10.1086/655468",
language = "English (US)",
volume = "202",
pages = "705--716",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - AIDS clinical trials group 5197

T2 - A placebo-controlled trial of immunization of HIV-1-infected persons with a replication-deficient adenovirus type 5 vaccine expressing the HIV-1 core protein

AU - Schooley, Robert T.

AU - Spritzler, John

AU - Wang, Hongying

AU - Lederman, Michael M.

AU - Havlir, Diane

AU - Kuritzkes, Daniel R.

AU - Pollard, Richard B

AU - Battaglia, Cathy

AU - Robertson, Michael

AU - Mehrotra, Devan

AU - Casimiro, Danilo

AU - Cox, Kara

AU - Schock, Barbara

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Background. Human immunodeficiency virus type 1 (HIV-1)-specific cellular immunity contributes to the control of HIV-1 replication. HIV-1-infected volunteers who were receiving antiretroviral therapy were given a replication-defective adenovirus type 5 HIV-1 gag vaccine in a randomized, blinded therapeutic vaccination study. Methods. HIV-1-infected vaccine or placebo recipients underwent analytical treatment interruption (ATI) for 16 weeks. The log10 HIV-1 RNA load at the ATI set point and the time-averaged area under the curve served as coprimary end points. Immune responses were measured by intracellular cytokine staining and carboxyfluorescein succinimidyl ester dye dilution. Results. Vaccine benefit trends were seen for both primary end points, but they did not reach a prespecified significance level of . The estimated P ≤.025 shifts in the time-averaged area under the curve and the ATI set point were 0.24 (P=.04 , unadjusted) and 0.26 ( P=.07, unadjusted) log10 Pp.04 Pp.07 copies lower, respectively, in the vaccine arm than in the placebo arm. HIV-1 gag-specific CD4+ cells producing interferon-γ were an immunologic correlate of viral control. Conclusion. The vaccine was generally safe and well tolerated. Despite a trend favoring viral suppression among vaccine recipients, differences in HIV-1 RNA levels did not meet the prespecified level of significance. Induction of HIV-1 gag-specific CD4 cells correlated with control of viral replication in vivo. Future immunogenicity studies should require a substantially higher immunogenicity threshold before an ATI is contemplated.

AB - Background. Human immunodeficiency virus type 1 (HIV-1)-specific cellular immunity contributes to the control of HIV-1 replication. HIV-1-infected volunteers who were receiving antiretroviral therapy were given a replication-defective adenovirus type 5 HIV-1 gag vaccine in a randomized, blinded therapeutic vaccination study. Methods. HIV-1-infected vaccine or placebo recipients underwent analytical treatment interruption (ATI) for 16 weeks. The log10 HIV-1 RNA load at the ATI set point and the time-averaged area under the curve served as coprimary end points. Immune responses were measured by intracellular cytokine staining and carboxyfluorescein succinimidyl ester dye dilution. Results. Vaccine benefit trends were seen for both primary end points, but they did not reach a prespecified significance level of . The estimated P ≤.025 shifts in the time-averaged area under the curve and the ATI set point were 0.24 (P=.04 , unadjusted) and 0.26 ( P=.07, unadjusted) log10 Pp.04 Pp.07 copies lower, respectively, in the vaccine arm than in the placebo arm. HIV-1 gag-specific CD4+ cells producing interferon-γ were an immunologic correlate of viral control. Conclusion. The vaccine was generally safe and well tolerated. Despite a trend favoring viral suppression among vaccine recipients, differences in HIV-1 RNA levels did not meet the prespecified level of significance. Induction of HIV-1 gag-specific CD4 cells correlated with control of viral replication in vivo. Future immunogenicity studies should require a substantially higher immunogenicity threshold before an ATI is contemplated.

UR - http://www.scopus.com/inward/record.url?scp=77955671541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955671541&partnerID=8YFLogxK

U2 - 10.1086/655468

DO - 10.1086/655468

M3 - Article

C2 - 20662716

AN - SCOPUS:77955671541

VL - 202

SP - 705

EP - 716

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -